Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.

Clinica chimica acta; international journal of clinical chemistry - 1 Jul 2009

He Yi-Jing, Zhang Wei, Chen Yao, Guo Dong, Tu Jiang-Hua, Xu Lin-Yong, Tan Zhi-Rong, Chen Bi-Lian, Li Zhi, Zhou Gan, Yu Bang-Ning, Kirchheiner Julia, Zhou Hong-Hao

Abstract excerpt

BACKGROUND: Both atorvastatin and rifampicin are substrates of OATP1B1 (organic anion transporting polypeptide 1B1) encoded by SLCO1B1 gene. Rifampicin is a potent inhibitor of SLCO1B1 (IC50 1.5 umol/l) and SLCO1B1 521T>C functional genetic polymorphism alters the kinetics of atorvastatin in vivo. We hypothesize that rifampicin might influence atorvastatin kinetics in a SLCO1B1 polymorphism dependent manner....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atorvastatin
Share to Heptanoic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kinetics

Share to Liver-Specific Organic Anion Transporter 1

Share to Organic Anion Transporters

Share to Pyrroles

Share to Rifampin

Share to Thymidine

Source

Identifiers

PMID: 19374892
DOI: 10.1016/j.cca.2009.04.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.PMID 19374892Read ↗

Effects of two functionally important SLCO1B1 gene polymorphisms on pharmacokinetics of atorvastatin.Semantic proximity Read ↗

The effect of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Chinese people.Semantic proximity Read ↗

Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.Semantic proximity Read ↗

Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin.Semantic proximity Read ↗

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.Semantic proximity Read ↗

Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.Semantic proximity Read ↗

Rifampicin population pharmacokinetics and pharmacogenomic evaluation of SLCO1B1 gene in tuberculosis patients.Semantic proximity Read ↗

Meta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins.Semantic proximity Read ↗

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin BioavailabilitySemantic proximity Read ↗

Impact of OATP transporters on pharmacokinetics.Semantic proximity Read ↗

Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response.Semantic proximity Read ↗

Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.